Updates on intranasal nanomedicine design for central nervous system disease treatment

Abstract

Intranasal drug delivery exhibits therapeutic potential for the treatment of central nervous system (CNS) diseases, as it allows pharmaceuticals to bypass the blood-brain barrier (BBB) via the olfactory and trigeminal pathways. The primary advantage of this method lies in its non-invasiveness and low systemic toxicity. Nevertheless, this delivery method faces notable challenges, including limited nasal mucosal absorption and short residence time in the olfactory region. To address these limitations, intranasal nanomedicine has gained research attention. Nanomedicines can improve brain bioavailability by enhancing drug solubility, permeability, and stability. The following discussion summarizes recent advancements in nanotechnology-enabled nose-to-brain delivery systems, with the aim of synthesizing progress in the field and outlining future research directions.

Keywords

intranasal delivery / nanomedicine / formulation design / intranasal nanomedicine / central nervous system diseases

References

[1] Dighe S, Jog S, Momin M, Sawarkar S, Omri A. Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management. Pharmaceutics. 2023; 16: 58.

[2] Koo J, Lim C, Oh KT. Recent Advances in Intranasal Administration for Brain—Targeting Delivery: A Comprehensive Review of Lipid—Based Nanoparticles and Stimuli—Responsive Gel Formulations. Int J Nanomedicine. 2024; 19: 1767-807.

[3] Kong X, Wang G, Wei S, Zhang K, Gao Y, Li X, et al. Macro—micro spray characteristics of nasal spray: Bridging physicochemical properties to precision olfactory delivery. Chin Chem Lett: [Forthcoming]. 2025 [cited 2026 Feb 10]. Available from: https://www.sciencedirect.com/science/article/pii/S1001841725012628

[4] Huang Q, Chen X, Yu S, Gong G, Shu H. Research progress in brain—targeted nasal drug delivery. Front Aging Neurosci. 2024; 15: 1341295.

[5] Huang Q, Chen Y, Zhang W, Xia X, Li H, Qin M, et al. Nanotechnology for enhanced nose—to—brain drug delivery in treating neurological diseases. J Control Release. 2024; 366: 519—34.

[6] Anwar DM, Hedeya HY, Ghozlan SH, Ewas BM, Khattab SN. Surface—modified lipid—based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni—Suef Univ J Basic Appl Sci. 2024; 13: 106.

[7] Kang Y, Zhang S, Wang G, Yan Z, Wu G, Tang L, et al. Nanocarrier—Based Transdermal Drug Delivery Systems for Dermatological Therapy. Pharmaceutics. 2024; 16: 1384.

[8] Scicluna MC, Vella—Zarb L. Evolution of Nanocarrier Drug—Delivery Systems and Recent Advancements in Covalent Organic Framework—Drug Systems. Acs Applied Nano Materials. 2020; 3: 3097-115.

[9] Wei S, Zhai Z, Kong X, Wu C, Zhu B, Zhao Z, et al. The review of nasal drug delivery system: The strategies to enhance the efficiency of intranasal drug delivery by improving drug absorption. Int J Pharm. 2025; 676: 125584.

[10] Gandhi S, Shastri DH, Shah J, Nair AB, Jacob S. Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport. Pharmaceutics. 2024; 16: 481.

[11] Sastri KT, Gupta NV, Sharadha M, Chakraborty S, Kumar H, Chand P, et al. Nanocarrier facilitated drug delivery to the brain through intranasal route: A promising approach to transcend bio—obstacles and alleviate neurodegenerative conditions. J Drug Deliv Sci Technol. 2022; 75: 103656.

[12] Zhou J, Li F, Jia B, Wu Z, Huang Z, He M, et al. Intranasal delivery of small extracellular vesicles reduces the progress of amyotrophic lateral sclerosis and the overactivation of complement—coagulation cascade and NF—ĸB signaling in SOD1^G93A mice. J Nanobiotechnology. 2024; 22: 503.

[13] Agnihotri TG, Dahifale A, Gomte SS, Rout B, Peddinti V, Jain A. Nanosystems at Nexus: Navigating Nose—to—Brain Delivery for Glioblastoma Treatment. Mol Pharm. 2025; 22: 599-619.

[14] Gausterer JC, Schlager M, Ahmadi N, Nieratschker M, Dahm V, Wirth M, et al. A Novel Preparation Technique for Human Nasal Respiratory Mucosa to Disclose Its Glycosylation Pattern for Bioadhesive Drug Delivery. Pharmaceutics. 2023; 15: 973.

[15] Bilapatte A, More A, Satpute K, Syed SM. Formulation and evaluation of carbamazepine loaded ethosomal nasal in—situ gel for brain targeted drug delivery. J Holist Integr Pharm. 2025; 6: 57-63.

[16] Devdikar S, Shetkar B, Badagu R, Satpute K, Syed SM. QbD—Based Development and Optimization of Intranasal Levodopa Liposomal Spray for Improved Brain Targeting in Parkinson's Disease. J Pharm Innov. 2025; 20: 291.

[17] Wang G, Zhai Z, Wang W, Xia X, Guo H, Yue X, et al. Tailored Borneol—Modified Lipid Nanoparticles Nasal Spray for Enhanced Nose—to—Brain Delivery to Central Nervous System Diseases. ACS Nano. 2024; 18: 23684-701.

[18] Usama Ashhar M, Vyas P, Vohora D, Kumar Sahoo P, Nigam K, Dang S, et al. Amelioration of oxidative stress utilizing nanoemulsion loaded with bromocriptine and glutathione for the management of Parkinson’s disease. Int J Pharm. 2022; 618: 121683.

[19] Borrajo ML, Alonso MJ. Using nanotechnology to deliver biomolecules from nose to brain — peptides, proteins, monoclonal antibodies and RNA. Drug Deliv Transl Res. 2022; 12: 862—80.

[20] Rai G, Gauba P, Dang S. Recent advances in nanotechnology for Intra—nasal drug delivery and clinical applications. J Drug Deliv Sci Technol. 2023; 86: 104726.

[21] Clementino AR, Pellegrini G, Banella S, Colombo G, Cantù L, Sonvico F, et al. Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs. Mol Pharm. 2021; 18: 3132-46.

[22] Yue X, Guo H, Wang G, Li J, Zhai Z, Wang Z, et al. A tailored phytosomes based nose—to—brain drug delivery strategy: Silver bullet for Alzheimer’s disease. Bioactive Materials. 2025; 44: 97-115.

[23] Patharapankal EJ, Ajiboye AL, Mattern C, Trivedi V. Nose—to—Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders. Pharmaceutics. 2023; 16: 66.

[24] Duo YU, Ying SUN, Xin SHEN, Xin ZHANG, Shi—rui MAO. Spray pattern and plume geometry measurement method of nasal spray and its correlation with nasal deposition. Acta Pharmaceutica Sinica. 2022; 57: 2032—40.

[25] Hu X, Yue X, Wu C, Zhang X. Factors affecting nasal drug delivery and design strategies for intranasal drug delivery. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023; 52: 328-37. English, Chinese.

[26] D’Angelo D, Kooij S, Verhoeven F, Sonvico F, van Rijn C. Fluorescence—enabled evaluation of nasal tract deposition and coverage of pharmaceutical formulations in a silicone nasal cast using an innovative spray device. J Adv Res. 2023; 44: 227-32.

[27] Fang S, Rui X, Zhang Y, Yang Z, Wang W. Comparative study of nasal cavity drug delivery efficiency with different nozzles in a 3D printed model. PeerJ. 2024; 12: e17227.

[28] Chen Y, Zhang C, Huang Y, Ma Y, Song Q, Chen H, et al. Intranasal drug delivery: The interaction between nanoparticles and the nose—to—brain pathway. Adv Drug Deliv Rev. 2024; 207: 115196.

[29] Feng X, Jia P, Zhang D. Nanocarrier drug delivery system: promising platform for targeted depression therapy. Front Pharmacol. 2024; 15: 1435133.

[30] Xiao H, Guo Y, Liu H, Liu Y, Wang Y, Li C, et al. Structure—based design of charge—conversional drug self—delivery systems for better targeted cancer therapy. Biomaterials. 2020; 232: 119701.